PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview: Respiratory diseases • Asthma • COPD • Allergic rhinitis • Pulmonary hypertension • Cystic fibrosis • IPF • US FDA-approved respiratory drugs PART 06: Pipeline analysis • Information on some pipeline candidates PART 07: Market landscape • Five forces analysis PART 08: Market segmentation by class of drugs • Bronchodilators • Leukotriene antagonists • Mast cell stabilizers • Immunosuppressants • Combination of LABA/ICS • Tyrosine kinase inhibitors • Antifibrotic agents • Antihistamines • Endothelin (ET) receptor antagonist • Prostacyclin analogs • Phosphodiesterase inhibitors • Soluble guanylate cyclase (sGC) stimulators PART 09: Market segmentation by disease • Global asthma drugs market • Global COPD drugs market • Global allergic rhinitis drugs market • Global pulmonary hypertension drugs market • Global cystic fibrosis drugs market • Global IPF drugs market PART 10: Geographical segmentation • Global respiratory drugs market by geography 2015-2020 • Respiratory drugs market in Americas • Respiratory drugs market in EMEA • Respiratory drugs market in APAC PART 11: Market drivers • Promising late-stage pipeline molecules • Rise in prevalence of respiratory diseases • Increase in older adult population • High usage of tobacco • Increase in environmental pollution PART 12: Impact of drivers PART 13: Market challenges • Multiple patent expiries • Unknown etiology of asthma and IPF • Low diagnosis rates • Adverse effects of drugs • Increased preference for CAM PART 14: Impact of drivers and challenges PART 15: Market trends • Increasing awareness about respiratory diseases • Patient assistance programs • Usage of biologics • Self-medication using OTC products • Strategic alliances PART 16: Vendor landscape • Competitive scenario • Market share analysis 2015 • AstraZeneca • Boehringer Ingelheim • F. Hoffmann-La Roche • GlaxoSmithKline • Merck • Novartis • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Objectives of asthma management Exhibit 03: COPD: Prevalence in six EU countries Exhibit 04: Management of COPD Exhibit 05: Prevalence rate of allergic rhinitis in China Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis Exhibit 07: Non-pharmacological therapies for allergic rhinitis Exhibit 08: Prevalence of cystic fibrosis by country 2014 Exhibit 09: Treatment options for IPF Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015 Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions) Exhibit 13: Global respiratory drugs market by diseases 2015 Exhibit 14: Five forces analysis Exhibit 15: Global asthma drugs market 2015-2020 ($ billions) Exhibit 16: Key drivers and challenges of global asthma drugs market Exhibit 17: Global asthma drugs market by class of drugs 2015 Exhibit 18: Global COPD drugs market 2015-2020 ($ billions) Exhibit 19: Key drivers and challenges of global COPD drugs market Exhibit 20: Global COPD drugs market by class of drugs 2015 Exhibit 21: Global allergic rhinitis drugs market 2015-2020 ($ billions) Exhibit 22: Key drivers and challenges of global allergic rhinitis drugs market Exhibit 23: Global allergic rhinitis drugs market by class of drugs 2015 Exhibit 24: Global pulmonary hypertension drugs market 2015-2020 ($ billions) Exhibit 25: Key drivers and challenges for global pulmonary hypertension drugs market Exhibit 26: Global pulmonary hypertension drugs market by class of drugs 2015 Exhibit 27: Global cystic fibrosis drugs market 2015-2020 ($ billions) Exhibit 28: Key drivers and challenges for global cystic fibrosis drugs market Exhibit 29: Global cystic fibrosis drugs market by type of molecule 2015 Exhibit 30: Global IPF market 2015-2020 ($ billions) Exhibit 31: Key drivers and challenges for global IPF drugs market Exhibit 32: Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020 Exhibit 33: Global respiratory drugs market by geography 2015 Exhibit 34: Global respiratory drugs market revenue by geography 2015-2020 ($ billions) Exhibit 35: Respiratory drugs market in Americas 2015-2020 ($ billions) Exhibit 36: Respiratory drugs market in EMEA 2015-2020 ($ billions) Exhibit 37: Respiratory drugs market in APAC 2015-2020 ($ billions) Exhibit 38: Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020 Exhibit 39: Impact of drivers Exhibit 40: Impact of drivers and challenges Exhibit 41: Drugs that converted from Rx to OTC Exhibit 42: Global respiratory drugs market share analysis 2015 Exhibit 43: Top selling respiratory drugs based on their revenue in 2014 Exhibit 44: AstraZeneca: Percentage share of products sales by therapy area 2014 Exhibit 45: AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions) Exhibit 46: AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions) Exhibit 47: AstraZeneca: Key takeaways Exhibit 48: Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions) Exhibit 49: Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions) Exhibit 50: Boehringer Ingelheim: Key takeaways Exhibit 51: F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions) Exhibit 52: F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions) Exhibit 53: F. Hoffmann-La Roche: Key takeaways Exhibit 54: GlaxoSmithKline: Percentage share of products sales by therapy area 2014 Exhibit 55: GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions) Exhibit 56: GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions) Exhibit 57: GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions) Exhibit 58: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions) Exhibit 59: GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions) Exhibit 60: GlaxoSmithKline: Key takeaways Exhibit 61: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)1 Exhibit 62: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)2 Exhibit 63: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)2 Exhibit 64: Merck: Key takeaways4 Exhibit 65: Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)6 Exhibit 66: Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)6 Exhibit 67: Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)7 Exhibit 68: Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)7 Exhibit 69: Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)8 Exhibit 70: Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012-2014 ($ millions)8 Exhibit 71: Novartis: Key takeaways9

AstraZeneca, Boehringer Ingelheim, F.Hoffman-La Roche, GlaxoSmithKline, Merck, Novartis, Abbott, Actavis, Afferent Pharmaceuticals, Alere, Almirall, Amgen, AptarGroup, Astellas, Aurobindo, Axis Shield, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Rottapharm Madaus, Sanofi, Shionogi, Siemens Healthcare Diagnostics, Skyepharma, Sosei, Sunovion, Takeda Pharmaceutical , Teva, Theravance, United Therapeutics, Vectura, Vertex, Zai Lab.